RxDoctor Payments DataLook up a doctor →

Sunil Agrawal, MD

Nephrology · Tulsa, OKNPI 1093953747

Payments from drug & device makers

$40,222in general payments, 2019–2025

Across 829 payments — averaging $48.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$14K
  • Bayer$7K
  • Otsuka America Pharmaceutical, Inc.$5K
  • Calliditas Therapeutics US Inc.$3K
  • Amgen$2K
  • Vantive US Healthcare LLC$2K
  • plus $9K from 38 others

What the payments were for

  • Consulting fees$2,8507%
  • Speaking & faculty fees$19,83849%
  • Travel & lodging$1,0773%
  • Food & beverage$16,19340%
  • Education$2641%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,222 in reported general payments places this provider in the 90th percentile of 106 nephrology providers in Oklahoma.

See all nephrology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$218,149
Medicare patients
572
Services billed
1,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Thiola EcTiopronin11$85,717
FarxigaDapagliflozin Propanediol85$59,847
KerendiaFinerenone13$14,353
LokelmaSodium Zirconium Cyclosilicate13$10,929
Sevelamer Carbonate19$7,589
Calcitriol124$2,623
Calcium Acetate29$2,167
Torsemide32$971
Nifedipine ErNifedipine39$875
Hydralazine Hcl52$550
Doxazosin Mesylate46$430
Amlodipine Besylate68$348
Furosemide32$284
Spironolactone17$234
Carvedilol38$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$13,572$70,77698 claims
BayerKerendia$6,760$14,35313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 nephrology providers in Oklahoma.

Other nephrology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →